Navigation Links
OXiGENE Announces a Poster Presentation Highlighting Results from,its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study,MMD-213) at the 47th Annual Meeting of the Association of Research,in Vision and Ophthalmology

WALTHAM, Mass.--(BUSINESS WIRE)--May 7, 2007 - OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced today that the results of its Phase II combretastatin A4 phosphate (CA4P) clinical trial in myopic macular degeneration (MMD) was presented at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology (ARVO) in Fort Lauderdale, FL. The abstract may be viewed at www.arvo.org.

The following are the poster session details: -0-

Poster No.:   1457/B534

Abstract      Phase II Clinical Trial of Intravenous Combretastatin A4

 Title:        Phosphate in Patients With Subfoveal Choroidal

               Neovascular Membranes (CNV) in Pathologic Myopia

Presentation  Monday, May 07, 2007, 8:30 AM -10:15 AM

 Time:

The poster provided additional details from the ZYBRESTAT(TM) CA4P Phase II clinical trial (MMD-213) in Myopic Macular Degeneration, top-line results from which the Company previously announced on February 15, 2007. Based on the positive results from this study, in which 100% of patients met the primary endpoint of maintenance of visual acuity, the Company has held a pre-IND meeting with the FDA regarding topical ophthalmic formulations (eye drops and ocular mini-tabs), is proceeding with development of a topical formulation of ZYBRESTAT(TM), and anticipates filing and IND and initiating clinical studies with the formulation in early 2008.

About the Study (MMD-213):

MMD-213 was a Phase II, double-masked (physician and subject), dose-ranging, multi-center study designed to evaluate the safety and efficacy of intravenous CA4P for treating subfoveal choroidal neovascularization in subjects with pathologic myopia. Subjects were assigned to receive CA4P at doses of 27, 36 or 45 mg/m(2). A total of 23 subjects, 7-8 per arm, were enrolled. All subjects receive
'"/>




Page: 1 2 3

Related medicine technology :

1. OXiGENE Abstracts Published in ASCO Program
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/11/2014)... According to a new ... Material, Application (Healthcare, Homeland security, Industrial application, Nuclear ... Hand-Held Instruments, Fixed, and Installed Instruments) & Geography ... by MarketsandMarkets, the Scintillator Market is expected to ... to 2020, and reach $479.16 Million in 2020. ...
(Date:7/11/2014)... 2014 According to a new ... Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - ... 2013-2019" the global endoscopy devices market was valued at ... grow at a CAGR of 6.8% from 2013 to ... billion in 2019. Browse the full Endoscopy ...
(Date:7/10/2014)... MUMBAI, India , July 11, 2014 /PRNewswire/ ... the treatment of cancer are being highlighted in ... Mumbai from 10-12 July, 2014.  Renowned ... meeting to share best practices and exchange knowledge ... more precise, accurate and efficient. ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... , NEW BRUNSWICK, N.J., Dec. 17 ... has opened the 2010 call for nominations. The $100,000 ... contributions towards the improvement of human health. Nomination ... be accepted until February 15, 2010. The Award winner ...
... LITTLE FALLS, N.J., Dec. 17 CANTEL MEDICAL CORP. ... Directors intends to pay, for the first time, a semiannual cash ... on the Company,s common stock. The Board declared the first cash ... paid on January 29, 2010 to shareholders of record at the ...
Cached Medicine Technology:Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research 2Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research 3Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research 4Cantel Medical Authorizes Semiannual Dividend 2
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular suppliers of ... its new range of elegant Quinceanera dresses . ... discounted prices. Worldwide clients can enjoy this special offer ... online shop, there are plenty of beautiful dresses for ... materials. MyDressCity.com’s hot items are prom gowns, bridesmaid gowns, ...
(Date:7/13/2014)... 13, 2014 Epidemiologists forecast an increase ... 6MM, from 8,062 diagnosed incident cases in 2013 to ... Growth Rate (AGR) of 4.35%, during the forecast period. ... of diagnosed incident cases of aGVHD in the 6MM, ... the lowest number of diagnosed incident cases of aGVHD, ...
(Date:7/13/2014)... ability to identify odors might indicate the development ... of the eye could indicate the build-up of ... brain, according to the results of four research ... Conference 2014 (AAIC 2014) in Copenhagen. , In ... identify odors was significantly associated with loss of ...
(Date:7/13/2014)... Wright & Schulte LLC has learned that the ... of 2015, in U.S. District Court, District of South ... process in the South Carolina federal court where ... multidistrict litigation (MDL). The complaints pending in the Louisiana ... that they took the statin medication to lower their ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4
... Antares, parent company, Medical Mutual of Ohio to ... processes, reduced costs, improved ... Software, developer of the,OnBase document and process management ... Management Solutions as the new provider of,enterprise document ...
... LISTERINE(R) Products Launch New Children,s Fluoride Rinse, with Special Tinting ... ... MORRIS PLAINS, N.J., March 11 Parents confess that kids,can ... care.,According to a recent survey of parents with children ages six ...
... of EUSA,s Transatlantic ... Commercialization Platform ... EUSA Raises Over US$50 Million to Fund Acquisition and Other ... Pharma Inc (,EUSA,), a transatlantic specialty pharmaceutical company,focused on oncology, ...
... LifeMasters Supported,SelfCare, Inc., a national leading ... announced it has received $15 million in ... one of its,earliest investors, Saints Capital, and ... financial flexibility to continue to execute on,its ...
... Will Address Attorney Weight Loss Coaching and Present Ideas On How ... ... Leventhal Weight Loss,Incorporated, the first in the nation executive weight ... that its president and founder Mark Leventhal, Esq. will address,the Washington, ...
... Made to Deny Union for Healthcare Employees in Ohio, ... (CNA) has launched an anti-union campaign against nurses,and other ... by the workers to unite in District 1199 of ... votes -- this Wednesday and Friday at nine Catholic,Healthcare ...
Cached Medicine News:Health News:Antares Management Solutions Selects Hyland Software's OnBase 2Health News:The Disappearing Toothbrush: Survey Reveals Kids' Top Excuses to Avoid Brushing 2Health News:The Disappearing Toothbrush: Survey Reveals Kids' Top Excuses to Avoid Brushing 3Health News:The Disappearing Toothbrush: Survey Reveals Kids' Top Excuses to Avoid Brushing 4Health News:EUSA Pharma to Acquire US Specialty Oncology Company Cytogen 2Health News:EUSA Pharma to Acquire US Specialty Oncology Company Cytogen 3Health News:EUSA Pharma to Acquire US Specialty Oncology Company Cytogen 4Health News:EUSA Pharma to Acquire US Specialty Oncology Company Cytogen 5Health News:LifeMasters Strengthens Capital Structure with $15 Million in Funding from Existing Investors 2Health News:LifeMasters Strengthens Capital Structure with $15 Million in Funding from Existing Investors 3Health News:Mark Leventhal To Address Nixon Peabody LLP 2Health News:SEIU: 'Union-Busting' by California Nurses Association 2
3 mm, 130 degree upwards cutting, detachable....
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Medicine Products: